# reload+after+2024-01-23 04:47:55.461822
address1§1000 Mylan Boulevard
city§Canonsburg
state§PA
zip§15317
country§United States
phone§724 514 1800
website§https://www.viatris.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
fullTimeEmployees§38000
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Scott Andrew Smith', 'age': 61, 'title': 'CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rajiv  Malik', 'age': 62, 'title': 'President & Executive Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 15354884, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sanjeev  Narula', 'age': 62, 'title': 'Chief Financial Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 2708400, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anthony  Mauro', 'age': 50, 'title': 'President of Developed Markets', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 9388764, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sanjeev Kumar Sethi', 'age': 56, 'title': 'Chief Operating Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul B. Campbell', 'age': 55, 'title': 'Chief Accounting Officer, Senior VP & Corporate Controller', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian S. Roman', 'age': 53, 'title': 'Global General Counsel', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Bayles', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jennifer  Mauer', 'title': 'Head of Global Communications & Corporate Brand', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew  Enrietti', 'title': 'Chief Human Relations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§6
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§0.48
dividendYield§0.0401
exDividendDate§1700611200
payoutRatio§0.3179
fiveYearAvgDividendYield§0.89
beta§1.132
priceToSalesTrailing12Months§0.9292912
currency§USD
dateShortInterest§1702598400
forwardEps§2.8
pegRatio§-1.57
exchange§NMS
quoteType§EQUITY
shortName§Viatris Inc.
longName§Viatris Inc.
firstTradeDateEpochUtc§322151400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d5d1873c-6bd3-3e7a-85a5-4c85b774dfd9
gmtOffSetMilliseconds§-18000000
targetHighPrice§35.0
targetLowPrice§9.0
targetMeanPrice§14.11
targetMedianPrice§11.0
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§9
quickRatio§0.775
earningsGrowth§-0.069
grossMargins§0.42926
ebitdaMargins§0.31892002
trailingPegRatio§None
